GENOMIC HEALTH, INC. Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 15th, 2005 • Genomic Health Inc • New York
c/o J.P. Morgan Securities Inc. 277 Park Avenue New York, New York 10172 c/o Lehman Brothers Inc. 745 Seventh Avenue New York, New York 10019 Ladies and Gentlemen:
FORM OF PROMISSORY NOTE (Equipment) To Master Security Agreement No. _________Promissory Note • July 15th, 2005 • Genomic Health Inc • Virginia
FOR VALUE RECEIVED, Genomic Health, Inc., a Delaware corporation, located at the address stated below (“Maker") promises, jointly and severally if more than one, to pay to the order of Oxford Finance Corporation or any subsequent holder hereof (each, a “Payee") at its office located at 133 N. Fairfax Street, Alexandria, VA 22314 or at such other place as Payee or the holder hereof may designate, the principal sum of Dollars ($ ), with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of ( %) per annum. Maker shall make three (3) payments of interest only as follows:
AMENDMENT TO SUBLEASESublease • July 15th, 2005 • Genomic Health Inc
THIS AMENDMENT TO SUBLEASE (“Amendment”) is entered into as of October 29, 2003 between Corixa Corporation and its affiliates, a Delaware corporation (“Tenant”) and Genomic Health, Inc., a Delaware corporation (“Subtenant”).
SECOND AMENDMENT TO SUBLEASESublease • July 15th, 2005 • Genomic Health Inc
THIS SECOND AMENDMENT TO SUBLEASE (“Amendment”) is entered into as of January 31, 2005, between Corixa Corporation and its affiliates, a Delaware corporation (“Tenant”) and Genomic Health, Inc., a Delaware corporation (“Subtenant”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. PATENT LICENSE AGREEMENTPatent License Agreement • July 15th, 2005 • Genomic Health Inc • California
THIS LICENSE AGREEMENT, dated as of March 30, 2001, is entered into between INCYTE GENOMICS, a Delaware corporation, with offices at 3160 Porter Drive, Palo Alto, California 94303 (“Incyte”), and Genomic Health, Inc., a Delaware corporation with offices at 101 University Avenue, Suite 220, Palo Alto, California 94301 (“GHI”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. July 19, 2002Collaborative Agreement • July 15th, 2005 • Genomic Health Inc
This letter amendment (“Second Amendment”) when signed on behalf of GHI as of the date hereof shall further amend the terms of the Original Agreement.
AMENDMENT TO THE LIFESEQ COLLABORATIVE AGREEMENTLifeseq Collaborative Agreement • July 15th, 2005 • Genomic Health Inc • California
This Amendment to the LifeSeq Collaborative Agreement (the “LifeSeq Amendment”) effective as of December 21, 2001 (the “Amendment Effective Date”), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (“Incyte”) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (“GHI”).
AMENDMENT TO COLLABORATION AND TECHNOLOGY TRANSFER AGREEMENTCollaboration and Technology Transfer Agreement • July 15th, 2005 • Genomic Health Inc • California
This Amendment to Collaboration and Technology Transfer Agreement (the “Collaboration Amendment”) effective as of December 21, 2001 (the “Amendment Effective Date”), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (“Incyte”) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (“GHI”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. COLLABORATION AND TECHNOLOGY TRANSFER AGREEMENTCollaboration and Technology Transfer Agreement • July 15th, 2005 • Genomic Health Inc • California
This Collaboration and Technology Transfer Agreement (the “Agreement”), effective as of March 30, 2001 (the “Effective Date”), is made by and between Genomic Health, Inc., a Delaware corporation, with a place of business at 101 University Ave, Suite 220, Palo Alto, CA 94301 (“GHI”) , and Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (“Incyte”).
MASTER SECURITY AGREEMENT No. 5081084 Dated as of March 30, 2005 (“Agreement”)Master Security Agreement • July 15th, 2005 • Genomic Health Inc • Virginia
THIS AGREEMENT is between Oxford Finance Corporation (together with its successors and assigns, if any, “Secured Party”) and Genomic Health, Inc. (“Debtor”). Secured Party has an office at 133 N. Fairfax Street, Alexandria, VA 22314. Debtor is a corporation organized and existing under the laws of the state of Delaware. Debtor’s mailing address and chief place of business is 301 Penobscot Drive, Redwood City, CA 94063.
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LIFESEQ COLLABORATIVE AGREEMENT between INCYTE GENOMICS, INC. And GENOMIC HEALTH, INC.Collaborative Agreement • July 15th, 2005 • Genomic Health Inc • California
This Agreement is entered into as of this 30th day of March, 2001 (the “Effective Date”) by and between Genomic Health, Inc., a Delaware corporation (“GHI”), having its principal place of business at 101 University Ave., Suite 220, Palo Alto, CA 94301, and Incyte Genomics, Inc., a Delaware corporation (“Incyte”), having its principal place of business at 3160 Porter Drive, Palo Alto, CA 94304.
SUBLEASE AGREEMENTSublease Agreement • July 15th, 2005 • Genomic Health Inc • Washington
THIS SUBLEASE AGREEMENT (“Sublease Agreement’), effective June 1, 2001 is entered into by and between Corixa Corporation and its affiliates, a Delaware corporation (“Tenant”), having its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, and Genomic Health, Inc., a Delaware corporation having its principal place of business after the Commencement Date at the Sublease Premises (“Subtenant”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. Amendment #3 to LifeSeq® Collaborative AgreementLifeseq® Collaborative Agreement • July 15th, 2005 • Genomic Health Inc
This Amendment to the LifeSeq® Collaborative Agreement (this “Amendment”) is entered into as of October 25,2004 (the “Amendment Effective Date”) by and between Incyte Corporation (f/k/a Incyte Genomics, Inc.), a Delaware Corporation (“Incyte”) and Genomic Health, Inc., a Delaware corporation (“GHI”).
GENOMIC HEALTH, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT February 9, 2004Investors’ Rights Agreement • July 15th, 2005 • Genomic Health Inc • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of February 9, 2004, by and among Genomic Health, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor.”
PCR Patent License Agreement BY AND BETWEEN Roche Molecular Systems, Inc. AND Genomic Health, Inc.Patent License Agreement • July 15th, 2005 • Genomic Health Inc
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. AMENDMENT TO THE PATENT LICENSE AGREEMENTPatent License Agreement • July 15th, 2005 • Genomic Health Inc • California
This Amendment to the Patent License Agreement (the “License Amendment”) effective as of December 21, 2001 (the “Amendment Effective Date”), is entered into by and between Incyte Genomics, Inc., a Delaware corporation, with a place of business at 3160 Porter Drive, Palo Alto, CA 94304 (“Incyte”) and Genomic Health, Inc., a Delaware corporation, with a place of business at 301 Penobscot Drive, Redwood City, CA 94063 (“GHI”).
